Revvity (RVTY) FDA Approvals $124.46 +3.52 (+2.91%) Closing price 09/11/2026 03:58 PM EasternExtended Trading$124.35 -0.11 (-0.09%) As of 09/11/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Revvity's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Revvity (RVTY). Over the past two years, Revvity has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as T1D. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. T1D 4-plex FDA Regulatory Events T1D 4-plex is a drug developed by Revvity for the following indication: diabetic ketoacidosis (DKA). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Provided Update - October 2,2025Provided Update Drug: T1D 4-plexAnnounced Date: October 2, 2025Indication: diabetic ketoacidosis (DKA)Other Companies Involved: NASDAQ:SNY AnnouncementRevvity, Inc. announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay.AI SummaryRevvity, Inc. and Sanofi have launched a program to expand testing for type 1 diabetes (T1D) by creating a new population‐scale assay for early detection. Building on Revvity’s research‐use 3-plex assay, the companies will develop a T1D 4-plex in vitro diagnostic (IVD) test. This assay will run on Revvity’s high‐throughput GSP® instrument and use both capillary dried blood spots and standard blood draws. By spotting autoimmune markers earlier, doctors can intervene sooner to slow disease progression and reduce the risk of serious complications like diabetic ketoacidosis. The collaboration will support clinical validation and regulatory filings, including submissions to the U.S. FDA and European IVDR authorities. In parallel, Revvity Omics will expand its existing lab-developed T1D test beyond its Pittsburgh facility, making the assay available at multiple global labs for broader patient access.Read Announcement Revvity FDA Events - Frequently Asked Questions Has Revvity received FDA approval? As of now, Revvity (RVTY) has not received any FDA approvals for its therapy in the last two years. What drugs has Revvity submitted to the FDA? In the past two years, Revvity (RVTY) has reported FDA regulatory activity for T1D 4-plex. What is the most recent FDA event for Revvity? The most recent FDA-related event for Revvity occurred on October 2, 2025, involving T1D 4-plex. The update was categorized as "Provided Update," with the company reporting: "Revvity, Inc. announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay." What conditions do Revvity's current drugs treat? Currently, Revvity has one therapy (T1D 4-plex) targeting the following condition: diabetic ketoacidosis (DKA). More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Agenus FDA EventsBioLineRx FDA EventsCAMP4 Therapeutics FDA EventsCompass Pathways FDA EventsJaguar Animal Health FDA EventsLegend Biotech FDA EventsLyell Immunopharma FDA EventsMedicus Pharma FDA EventsOncolytics Biotech FDA EventsOptimi Health FDA EventsOncobiologics FDA EventsPrelude Therapeutics FDA EventsVerrica Pharmaceuticals FDA EventsAbbVie FDA EventsAscendis Pharma A/S FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Agilent Technologies FDA Events Qiagen FDA Events Adaptive Biotechnologies FDA Events Personalis FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NYSE:RVTY last updated on 10/2/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersElon’s “nude” scandal – a big opportunity?Elon Musk's SpaceX just hit a legal snag in Minnesota over Grok's AI nudification capabilities, with the state...InvestorPlace | SponsoredGold led me to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...Stansberry Research | SponsoredWhy I'm NOT Buying the SpaceX IPO (And What I'm Buying Instead)Don't buy Nvidia... Not when the AI companies that will define the next decade are selling for pennies. You wo...Decentralized Masters | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredShocking AI prediction from the “Billionaire Whisperer"Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | SponsoredAfter KDA, PRE, and OCEAN—this is the one17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revvity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revvity With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Provided Update - October 2,2025Provided Update Drug: T1D 4-plexAnnounced Date: October 2, 2025Indication: diabetic ketoacidosis (DKA)Other Companies Involved: NASDAQ:SNY AnnouncementRevvity, Inc. announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay.AI SummaryRevvity, Inc. and Sanofi have launched a program to expand testing for type 1 diabetes (T1D) by creating a new population‐scale assay for early detection. Building on Revvity’s research‐use 3-plex assay, the companies will develop a T1D 4-plex in vitro diagnostic (IVD) test. This assay will run on Revvity’s high‐throughput GSP® instrument and use both capillary dried blood spots and standard blood draws. By spotting autoimmune markers earlier, doctors can intervene sooner to slow disease progression and reduce the risk of serious complications like diabetic ketoacidosis. The collaboration will support clinical validation and regulatory filings, including submissions to the U.S. FDA and European IVDR authorities. In parallel, Revvity Omics will expand its existing lab-developed T1D test beyond its Pittsburgh facility, making the assay available at multiple global labs for broader patient access.Read Announcement
